Peptides for Gut Health: BPC-157, KPV, and What to Rule Out First

The intestinal epithelium is a single layer of cells renewed roughly every three to five days from stem cells at the base of each crypt, faster than almost any other tissue in the body, which is why it is both easily damaged and, in principle, quick to repair. Damage comes from acid and pepsin, NSAIDs and alcohol, bile acids, infection, and immune attack in inflammatory bowel disease. Repair depends on blood supply, on cells migrating across the wound, and on signals that tell them to proliferate. Most of what is described for BPC-157 in the animal literature concerns those three things.

Between the epithelial cells sit tight-junction proteins that regulate what passes from the gut lumen into the tissue beneath. Increased intestinal permeability is real and measurable; a 2019 review in Gut sets out how it is measured in humans and where it has been documented (celiac disease, inflammatory bowel disease, some people with irritable bowel syndrome). That review is also clear that "leaky gut" as a standalone diagnosis is not an established clinical entity, and that increased permeability is more often a consequence of disease than its cause. When a page attributes fatigue, skin complaints and food sensitivities to a leaky gut, it is usually describing symptoms that a specific, testable condition would explain better.

The gut holds the largest concentration of immune tissue in the body. In inflammatory bowel disease that tissue attacks the lining itself; in a functional disorder such as irritable bowel syndrome the lining is intact and the problem is motility, sensitivity and signaling. The distinction matters because KPV is an anti-inflammatory fragment whose animal work is in colitis, a model of inflamed tissue; there is no reason from the literature to expect it to do much in a gut that is not inflamed. Fecal calprotectin and C-reactive protein answer that question, and it is worth answering before choosing between BPC-157 and KPV.

The enteric nervous system communicates with the brain in both directions through the vagus nerve, immune signaling and the microbiome, which is why stress changes bowel habit and why gut symptoms and mood travel together. A 2016 review in Current Neuropharmacology describes BPC-157 in terms of this brain-gut axis, and it is why ELEVATE pairs BPC-157 and KPV with two neuro-oriented peptides. It is also the part of the literature most often overstated.

A pentadecapeptide, fifteen amino acids in the sequence GEPPPGKPADDAGLV, a partial sequence of a larger protein isolated from human gastric juice. The literature calls it "stable gastric pentadecapeptide BPC 157" because it was reported to remain intact in gastric juice for hours, which is unusual for a peptide and the reason oral and rectal formats were ever studied.

The gut is where the research began. A 2011 review in Current Pharmaceutical Design summarizes the animal work: protection of the stomach lining against NSAIDs and alcohol, healing of ulcers along the upper gut, and effects in colitis and on surgical joins in the bowel. A 2013 paper in the same journal is devoted to NSAID toxicity in rats. A 2013 paper in the Journal of Physiology and Pharmacology reports rats with cysteamine-induced colitis and colon anastomoses healing more completely with BPC-157; a 2016 paper in the European Journal of Pharmacology describes closure of a colovesical fistula; a 2020 review in Current Pharmaceutical Design gathers the fistula work; a 2016 paper in PLoS One reports improved intestinal adaptation in rats with surgically shortened bowel; and 2024 and 2025 reviews in Pharmaceuticals collect the anastomosis studies and the wider literature.

The mechanisms described are the same ones that make BPC-157 interesting for tendons: new blood-vessel formation through the VEGF receptor pathway, interaction with the nitric-oxide system, and cell migration into the wound. A 2020 paper in Current Pharmaceutical Design adds a barrier-specific finding: in cell and rat models of NSAID damage, BPC-157 was reported to stabilize intestinal permeability and tight-junction integrity. That is the paper behind the "leaky gut" claims, and it is a cell and rodent study.

The reviewed directions on the BPC-157 product page are 0.18 mL, 18 units on a U-100 insulin syringe, subcutaneously once daily as directed, 27 doses per vial and about 3.9 weeks of coverage; it is also available as a pre-filled Pen cartridge. It suits the person whose complaint is the lining itself: upper-gut soreness after NSAID use, recovery after a properly managed flare, or a functional complaint with no red flags and normal investigations. The reference page is what is BPC-157.

The last three amino acids of alpha-melanocyte-stimulating hormone: lysine, proline, valine. Isolating that fragment is described as keeping the anti-inflammatory signaling of the parent hormone without its pigmentation effect; a 2008 review in Endocrine Reviews covers the biochemistry of alpha-MSH and its tripeptides in immune-mediated inflammatory disease models.

The gut-specific finding is transport. A 2008 paper in Gastroenterology reported that KPV enters intestinal epithelial cells through PepT1, a peptide transporter upregulated in inflamed intestinal tissue, and that oral KPV reduced inflammation in mouse colitis, with reduced NF-kB activation and lower pro-inflammatory cytokine production. The tissue that is inflamed is the tissue most able to take it up. A 2008 paper in Inflammatory Bowel Diseases reported reduced colitis severity in two mouse models, and a 2017 paper in Molecular Therapy described KPV in hyaluronic-acid nanoparticles for targeted oral delivery in mouse colitis. A 2012 paper in the International Journal of Physiology, Pathophysiology and Pharmacology describes the intracellular mechanism in human airway cells, including interference with NF-kB signaling.

What KPV does not have is any human study. The FDA's review for the July 2026 advisory committee states that no published studies were found in which drug products containing KPV were used in humans, and that none of the nine references the nominator cited were human studies.

The reviewed directions on the KPV product page are 0.25 mL, 25 units, subcutaneously once daily Monday through Friday, 20 doses per vial and about four weeks of coverage. It suits the person whose gut complaint is inflammation-led, with a documented inflammatory picture or an inflammatory component the physician wants to address. The reference page is what is KPV.

KLOW combines BPC-157, KPV, TB-500 and GHK-Cu in one vial. TB-500 is a fragment related to thymosin beta-4, an actin-binding protein described in a 2005 review in Trends in Molecular Medicine as promoting cell migration into injured tissue. GHK-Cu is a copper-carrying tripeptide described in a 2015 review in BioMed Research International as modulating collagen synthesis and tissue remodeling. Neither is a gut peptide. KLOW suits the person with a gut complaint and, at the same time, a skin or connective-tissue reason to be treated, who would otherwise be on two vials. Directions are 0.25 mL, 25 units, subcutaneously on weekday mornings, 20 doses per vial. The repair side is explained in peptides for healing.

FORTIFY combines thymosin alpha-1, BPC-157, KPV and LL-37. Thymosin alpha-1 is a 28-amino-acid peptide produced by the thymus, described as modulating immune function through T-cell maturation and Toll-like receptor signaling. It is the one component on this page with a real human trial record: a 1998 randomized controlled trial in Hepatology in chronic hepatitis B, a 2026 Cochrane review of the hepatitis B trials, and a 2025 phase 3 trial in the BMJ in sepsis. None is a gut indication. LL-37 is a human antimicrobial peptide reviewed in Biochimica et Biophysica Acta in 2006; its human data are two randomized trials of a topical preparation in venous leg ulcers, in Wound Repair and Regeneration in 2014 and 2021. FORTIFY suits the person whose gut symptoms sit alongside frequent infections or a physician-identified immune reason for thymosin alpha-1; see peptides for immune support. Directions are 0.25 mL, 25 units, subcutaneously once daily Monday through Friday, 20 doses per vial.

ELEVATE combines Semax, Selank, BPC-157 and KPV. Semax is related to a fragment of ACTH without its hormonal activity; a 2006 paper in Brain Research describes it regulating BDNF expression in the rat hippocampus. Selank is related to tuftsin and is described as modulating GABAergic and serotonergic signaling; its human record is Russian-language clinical work in anxiety, including a 2014 comparison with a benzodiazepine. They address the mood and focus side of a gut-brain presentation, not the intestine. ELEVATE suits the person whose gut complaint and mood or concentration complaint are entangled. Directions are 0.25 mL, 25 units, subcutaneously once daily Monday through Friday, 20 doses per vial.

The BPC-157 + TB-500 stack is for the person with a gut complaint and a soft-tissue injury at the same time; TB-500 adds nothing gut-specific. Directions are 0.25 mL, 25 units, subcutaneously on weekday mornings, 20 doses per vial.

The rodent literature on BPC-157 and the gut runs to decades of work and is internally consistent: protection against chemical and drug injury, healing of ulcers, fistulas and surgical joins, and a wide reported margin between effective doses and doses that cause problems. The FDA's own reviewers, in the briefing prepared for the July 2026 advisory committee, acknowledged that nonclinical studies reported BPC-157 preventing colonic fistulas and gastrointestinal lesions in rats, while noting that dose-response relationships had not been established, that the molecular targets had not been identified, and that the mechanisms remained poorly understood.

This is the honest part. The FDA's review identified a single meeting abstract, from 2005, reporting a multicenter randomized, double-blind, placebo-controlled study of BPC-157 (as PL 14736) given as an enema for two weeks to 53 people with mild to moderate ulcerative colitis. The reported change in disease activity was larger in the BPC-157 group, but the confidence interval for the difference between groups crossed zero, and because the trial was never published in full, the inclusion criteria, endpoint definition and statistics are unknown; the reviewers judged the data inadequate to support efficacy. Beyond that they found a phase 1 study of an oral tablet in healthy volunteers with no results posted, and a 2025 pilot report of intravenous infusion in two healthy subjects. In the enema studies the most frequently reported adverse events were headache and flatulence, with no serious adverse events. The reviewers found no studies that administered BPC-157 to humans by the oral, subcutaneous, nasal or transdermal route in ulcerative colitis, and no human pharmacokinetic data at all.

So the accurate sentence is not "no human trials." It is: the only randomized human trial of BPC-157 in a gut condition is a two-week enema study reported as a conference abstract two decades ago, and there is no randomized human trial of the injectable form for any gut indication.

KPV has no human studies. That is the FDA's finding, not an inference: no published studies in which KPV products were used in humans, no outsourcing-facility reports of KPV being compounded between January 2017 and June 2025, and a nomination whose supporting references were all animal or cell work. The FDA also noted that KPV is promoted online for inflammatory bowel disease, Crohn's disease, mast cell activation and histamine intolerance, none of it supported by human evidence. The animal colitis work is real and mechanistically coherent; it is also all there is.

Thymosin alpha-1 has genuine randomized trials in hepatitis B, hepatitis C and sepsis, and no gut trial. LL-37 has two randomized trials of a topical wound preparation. TB-500 has a 2010 randomized safety study of intravenous thymosin beta-4 in healthy volunteers, in Annals of the New York Academy of Sciences. GHK-Cu's human data are in skin; Semax and Selank have Russian-language clinical literature in stroke and anxiety. None of that transfers to the intestine, and a blend does not inherit evidence from a component's unrelated indication. What the evidence does not establish, for any product here, is an effect size in humans with a gut complaint, a timeline, or long-term safety over years of use. A provider who tells you a peptide will repair your gut lining in a stated number of weeks is inventing it.

Between 2023 and early 2026 BPC-157, KPV, TB-500, injectable GHK-Cu, LL-37 and Semax all sat in Category 2 of the FDA's interim 503A bulk drug substances list, the category for nominated substances flagged as presenting significant safety risks. On 15 April 2026 the FDA announced it was removing twelve peptides from Category 2, effective about a week later, because the nominations that had placed them there were withdrawn; the agency was careful to say that removal does not by itself establish that a substance meets the criteria for compounding. The FDA's safety-risks page, updated 22 April 2026, now lists BPC-157, KPV, TB-500, GHK-Cu, LL-37, Semax, Selank and thymosin alpha-1 only under "nominated but withdrawn," and none remains in Category 2.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 (free base and acetate) for ulcerative colitis, KPV (free base and acetate) for wound healing and inflammatory conditions, and TB-500 for wound healing. The committee voted 8 to 6, with one abstention in each case, to recommend adding all three to the 503A Bulks List.

Those votes went against the FDA's own staff. The BPC-157 briefing concluded that "a balancing of the criteria weighs against" listing, citing limited characterization, the lack of evidence of effectiveness in ulcerative colitis, and insufficient clinical safety information. The KPV briefing reached the same conclusion, adding that the substance was not well characterized and that the extent of its use in compounding was unknown. A committee vote is a recommendation; the FDA issues its own determination through rulemaking, and as of September 2026 that determination is pending.

Thymosin alpha-1 left Category 2 earlier, after its nomination was withdrawn in 2024, and was reviewed on its own. On 4 December 2024 the committee voted 4 in favor and 17 against adding thymosin alpha-1 (free base) and its acetate to the 503A Bulks List, after reviewing uses that included hepatitis B and C, HIV, COVID-19, depressed vaccine response, several cancers and sepsis; members who voted no said there was no compelling evidence of clinical effectiveness and safety for those uses. The FDA has not issued a final rule, and thymosin alpha-1 was not on the July 2026 agenda.

Semax was reviewed on 24 July 2026 and recommended by 8 votes to 5, with one abstention. GHK-Cu and LL-37 were not on the July agenda; the FDA has said the committee will consider them, with three other peptides, at a meeting before the end of February 2027. Selank's nomination was withdrawn in 2024 and it has never been reviewed.

As of September 2026, none of the components in any product on this page is in Category 2 or otherwise restricted. BPC-157, KPV, TB-500 and Semax are recommended for the positive list and await final FDA action; GHK-Cu and LL-37 are scheduled for review; thymosin alpha-1 received a negative recommendation the FDA has not acted on; Selank has never been reviewed. All remain legal to prescribe and compound. None is an FDA-approved drug product, and compounded medications never are. See are peptides FDA approved.

The 2026 WADA Prohibited List, in effect from 1 January 2026, names BPC-157 under S0, non-approved substances, prohibited at all times, and lists thymosin beta-4 and its derivatives, naming TB-500, under S2 peptide hormones and growth factors. USADA's guidance says the same of BPC-157. KPV is not named, but S0 covers any substance without regulatory approval for human use, and a tested athlete should assume every product on this page is prohibited.

What is reported early is usually not the lining changing but symptom intensity settling, where it does. Some people notice nothing in this window, which is normal and not a sign the treatment is not working. Injection-site redness or mild soreness is the most common thing reported.

This is where tissue-level change would be expected if it occurs, based on the animal timelines, and it is the window patients most commonly describe change in. Treatment is long-term, supplied one vial per fill on 28-day refills, and your physician stays reachable for dose questions and side effects.

A gut complaint that has run for years is generally described as slower to change than one that followed a recent NSAID course, an infection or a flare. That is worth discussing with your physician before starting rather than after, and it is why the intake asks how long the symptoms have been present and what has already been tried.